- Home
- PGRE vs PHVS Comparison
PGRE vs PHVS Comparison
Compare PGRE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- PHVS
- Stock Information
- Founded
- PGRE 1978
- PHVS 2015
- Country
- PGRE United States
- PHVS Netherlands
- Employees
- PGRE N/A
- PHVS N/A
- Industry
- PGRE Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- PHVS Health Care
- Exchange
- PGRE Nasdaq
- PHVS Nasdaq
- Market Cap
- PGRE 1.0B
- PHVS 1.0B
- IPO Year
- PGRE 2014
- PHVS 2021
- Fundamental
- Price
- PGRE $4.97
- PHVS $18.54
- Analyst Decision
- PGRE Hold
- PHVS Strong Buy
- Analyst Count
- PGRE 3
- PHVS 5
- Target Price
- PGRE $4.50
- PHVS $40.60
- AVG Volume (30 Days)
- PGRE 1.0M
- PHVS 66.5K
- Earning Date
- PGRE 02-12-2025
- PHVS 11-13-2024
- Dividend Yield
- PGRE 1.42%
- PHVS N/A
- EPS Growth
- PGRE N/A
- PHVS N/A
- EPS
- PGRE N/A
- PHVS N/A
- Revenue
- PGRE $553,641,000.00
- PHVS N/A
- Revenue This Year
- PGRE N/A
- PHVS N/A
- Revenue Next Year
- PGRE N/A
- PHVS N/A
- P/E Ratio
- PGRE N/A
- PHVS N/A
- Revenue Growth
- PGRE N/A
- PHVS N/A
- 52 Week Low
- PGRE $4.21
- PHVS $15.37
- 52 Week High
- PGRE $5.47
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- PGRE 55.64
- PHVS 42.23
- Support Level
- PGRE $4.74
- PHVS $18.18
- Resistance Level
- PGRE $4.94
- PHVS $19.88
- Average True Range (ATR)
- PGRE 0.15
- PHVS 1.17
- MACD
- PGRE 0.02
- PHVS 0.08
- Stochastic Oscillator
- PGRE 88.24
- PHVS 23.92
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.